Table 1 Baseline, mutation characteristics, treatment, and outcomes
Patient | Reference | ||||||||
|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | ||
Baseline characteristics | |||||||||
Age (years) | 50 | 67 | 60 | 51 | 65 | 59 | 55 | 60 | |
Sex | male | male | female | female | female | male | male | male | |
Surgery | Yes | Yes | Yes | No | Yes | Yes | No | Yes | |
Stage | IIIb | IIIb | IIIb | IIIb | IIIb | IIIb | IV | IIIb | |
Lymph node metastasis | + | – | + | + | + | + | + | + | |
Virus infection | HBV | NHVI | NHVI | NHVI | NHVI | NHVI | HCV | HBV | |
Tumour PD-L1 expression level (%) | < 5% | < 5% | < 1% | unknown | > 90% | > 90% | unknown | < 5% | |
Percentage of CD8+ T cells | 10% | 10% | 10% | unknown | 20% | 20% | unknown | 30% | |
Mutation characteristics | |||||||||
TMB (mutations/Mb) | 2.95 | 7.09 | 5.62 | 4.18 | 8.47 | 34.84 | 5.38 | 6.01 | 7.4 (median) [21] |
TMB (NSM) | 25 | 163 | 114 | 66 | 209 | 1088 | 106 | 127 | 47 (median) [22] |
Number of SNVs | 13 | 54 | 85 | 52 | 173 | 771 | 82 | 105 | 41 (median) [22] |
Number of indels | 12 | 109 | 29 | 14 | 36 | 317 | 24 | 22 | 6 (median) [22] |
indels ratio (%) | 48.00% | 66.87% | 25.44% | 21.21% | 17.22% | 29.16% | 22.64% | 17.32% | 12.77% (median) [22] |
MSI-H/MSS | MSS | MSS | MSS | MSS | MSS | MSI-H | MSS | MSS | 3.2% MSI-H [20] |
dMMR/pMMR | pMMR | pMMR | pMMR | pMMR | pMMR | dMMR | pMMR | pMMR | 2% dMMR [10] |
Percentage of CNVs (%) | 3.1 | 4.2 | 9.29 | 2.66 | 4.75 | 0.78 | 3.67 | 5.92 | |
Mutations conferring sensitivity to immunotherapy | NA | TP53/PTEN | KRAS | NA | BRAF/GITR | MLH1/GITR | TP53 | TP53 | |
Mutations conferring resistance to immunotherapy | JAK2 | B2M | chromosome 11q13 | ||||||
Treatment | |||||||||
Therapeutic regimen (cycles) | tegafur (3) + pembrolizumab (15) + cyberknife (2) | tegafur (5, but irregular) + pembrolizumab (6) | nivolumab (4) + cisplatin (1) + gemcitabine (1) | nivolumab (15) | nivolumab (8) | nivolumab (8) + cisplatin (1) + gemcitabine (1) | nivolumab (8) + lenvatinib (8 months continuously) | pembrolizumab (6) | |
Outcome | |||||||||
Type of response | CR | CR | PD | SD | PD | PR | PD | PR | |
PFS (months) | 16 | 13 | Unknown | 7 | 5 | 3 | Unknown | 10 | |